Editas Medicine
Stock Forecast, Prediction & Price Target
Editas Medicine Financial Estimates
Editas Medicine Revenue Estimates
Editas Medicine EBITDA Estimates
Editas Medicine Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $25.54M N/A | $19.71M -22.83% | $78.12M 296.32% | Avg: $24.82M Low: $16.99M High: $31.11M avg. -68.21% | Avg: $62.22M Low: $16.96M High: $107.09M avg. 150.59% | Avg: $187.78M Low: $51.20M High: $323.21M avg. 201.80% | Avg: $301.13M Low: $82.10M High: $518.31M avg. 60.36% |
Net Income
% change YoY
| $-185.10M N/A | $-204.35M -10.39% | $-153.21M 25.02% | Avg: $-250.37M Low: $-262.84M High: $-130.66M avg. -63.40% | Avg: $-261.40M Low: $-233.97M High: $-129.14M avg. -4.40% | Avg: $-124.49M Low: $-241.22M High: $-6.78M avg. 52.37% | Avg: $-58.20M Low: $-112.78M High: $-3.17M avg. 53.24% |
EBITDA
% change YoY
| $-193.14M N/A | $-225.95M -16.98% | $-163.11M 27.80% | Avg: $-24.82M Low: $-31.11M High: $-16.99M avg. 84.77% | Avg: $-62.22M Low: $-107.09M High: $-16.96M avg. -150.59% | Avg: $-187.78M Low: $-323.21M High: $-51.20M avg. -201.80% | Avg: $-301.13M Low: $-518.31M High: $-82.10M avg. -60.36% |
EPS
% change YoY
| -$2.74 N/A | -$2.98 -8.75% | -$2.02 32.21% | Avg: -$2.55 Low: -$3.46 High: -$1.72 avg. -26.21% | Avg: -$2.49 Low: -$3.08 High: -$1.7 avg. 2.38% | Avg: -$1.64 Low: -$3.18 High: -$0.09 avg. 34.15% | Avg: -$0.77 Low: -$1.48 High: -$0.04 avg. 53.24% |
Operating Expenses
% change YoY
| $218.69M N/A | $245.66M 12.33% | $247.30M 0.66% | Avg: $56.36M Low: $38.58M High: $70.63M avg. -77.20% | Avg: $141.23M Low: $38.51M High: $243.10M avg. 150.59% | Avg: $426.26M Low: $116.22M High: $733.69M avg. 201.80% | Avg: $683.56M Low: $186.38M High: $1.17B avg. 60.36% |
FAQ
What is Editas Medicine stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 9.45% in 2025-2028.
We have gathered data from 13 analysts. Their low estimate is -262.84M, average is -250.37M and high is -130.66M.
What is Editas Medicine stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 86.13% in 2025-2028.
We have gathered data from 12 analysts. Their low revenue estimate is $16.99M, average is $24.82M and high is $31.11M.
What is Editas Medicine stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 15.89% in 2025-2028.
We have gathered data from 13 analysts. Their low earnings per share estimate is -$3.46, average is -$2.55 and high is $-1.72.
What is the best performing analyst?
In the last twelve months analysts have been covering Editas Medicine stock. The most successful analyst is Gena Wang.